Pfizer fights approval of generic Ibrance
21-10-2021
Novartis takes aim at Indian drug companies over Entresto generics
29-10-2019
II.studio / Shutterstock.com
The Delhi High Court has cleared the way for a generic version of Novartis’ small-cell lung cancer drug Ceritinib, after the Swiss pharmaceutical company’s patent was revoked.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Delhi High Court, Ceritinib, Novartis, Natco Pharma, Noxalk, controller-general, Intellectual Property Appellate Board, IPAB, cancer
